Paul Varki
General Counsel at Avalo Therapeutics, Inc. (AVTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $1.5M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 37,37541,322 held (−47%) | $18.91 | $707K | -27.8% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 5,19636,126 held (−13%) | $19.78 | $103K | -31.0% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 22,83913,287 held (−63%) | $21.22 | $485K | -35.7% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 9,2534,034 held (−70%) | $22.70 | $210K | -39.9% |
| May 7SEC | AVTXAvalo Therapeutics, Inc. | Sell Plan | 4003,634 held (−10%) | $23.71 | $9K | -42.4% |
- Sell
General Counsel Paul Varki sold $707K of AVTX at $18.91 — cuts the stake by 47%; pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Paul Varki sold $103K of AVTX at $19.78 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Paul Varki sold $485K of AVTX at $21.22 — cuts the stake by 63%; pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Paul Varki sold $210K of AVTX at $22.70 — cuts the stake by 70%; pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Paul Varki sold $9K of AVTX at $23.71 — pre-scheduled 10b5-1 plan sale.